EUCTR2011-003512-23-Outside-EU/EEA进行中（未招募）不适用
A phase II, randomized, observer blind, multicenter study to evaluate the safety and immunogenicity of a single low dose of AS03-adjuvanted, Quebec- or Dresden- manufactured monovalent A/California/7/2009 (H1N1)v-like vaccine in children 3 to less than 10 years old - FLU Q-PAN H1N1-AS03-045
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 209
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or pre-menarchal female children 3 to < 10 years of age at the time of the study vaccination. Less than 10 years of age” implies inclusion of children who have not reached their 10th birthday as of Day 0, the day of the study vaccine dose under this protocol.
- •Written informed consent obtained from the subject’s parent/legally acceptable representative (LAR); written informed assent obtained from the subject if appropriate.
- •Good general health as established by medical history and clinical examination before entering into the study.
- •Subjects and/or parent(s)/LAR who the investigator believes can and will comply with the requirements of the protocol as documented by signature on the informed consent document (and, if appropriate, the informed assent document).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 209
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Medical history of physician-confirmed infection with an A/California/7/2009 (H1N1)v-like virus.
- •Previous vaccination at any time with an A/California/7/2009 (H1N1)v-like virus vaccine.
- •Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, even if stable, are deemed by the investigator to render the potential subject or parent(s)/ LAR(s) unable/unlikely to provide accurate safety reports.
- •Presence of a temperature = 38.0ºC by any route or method, or acute symptoms greater than mild” severity on the scheduled date of vaccination.
- •Diagnosed with cancer, or treatment for cancer, within 3 years.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •Receipt of systemic glucocorticoids within 1 month prior to study enrollment (day of study vaccination), or any other cytotoxic or immunosuppressive drug within 6 months of study enrollment. Topical, intra-articular or inhaled glucocorticoids are allowed.
- •Receipt of any immunoglobulins and/or any blood products within 6 months of study enrollment or planned administration of any of these products during the study period.
- •Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin are eligible if no such doses are given in the 24 hours before a study vaccination. Persons receiving prophylactic antiplatelet medications, e.g., low-dose acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are eligible.
- •Administration of any licensed live-attenuated vaccine within 30 days before study vaccination or any licensed inactivated vaccine within 15 days before study vaccination.
- •Planned administration of any A/California H1N1v-like vaccine other than the study vaccine between Day 0 and the Day 21 phlebotomy.
- •Planned administration of any other vaccine not foreseen by the study protocol between Day 0 and Day 21. Routine childhood vaccinations are exempted if they cannot be delayed, but they must not be administered on the same day as the H1N1 vaccine candidate.
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding study vaccination, or planned use during the study period.
- •Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.
- •Child in care (A child who has been placed under the control or protection of an agency, organization, institution or entity by the courts).
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study toEvaluate the Safety and Immunogenicity of Chiron Meningococcal ACWY ConjugateVaccine in Healthy Children Aged 12-59 MonthsEUCTR2004-001896-21-FIChiron S.r.l.600
进行中（未招募）
不适用
Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months.InfluenzaEUCTR2014-004543-12-Outside-EU/EEAovartis Vaccines and Diagnostics Srl.350
进行中（未招募）
不适用
Immune Response Induced by a Trivalent Group B strep. vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings.Prophylaxis against Group B Streptococcus infection.EUCTR2010-020840-36-Outside-EU/EEAovartis Vaccines and Diagnostics100
进行中（未招募）
1 期
Testing a vaccine in pregnant woman to protect their newborn babies from blood poisoning caused by a bacteriumInvasive group B streptococcus diseaseMedDRA version: 13.1Level: PTClassification code 10053588Term: Group B streptococcus neonatal sepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-020840-36-BEovartis Vaccines and Diagnostics GmbH100
进行中（未招募）
1 期
Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV vaccine (GSK-580299) and Merck's Gardasil® vaccine when administered according to alternative 2-dose schedules in 9-14 years old femalesCervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic human papillomaviruses (HPV).MedDRA version: 14.0Level: LLTClassification code 10033723Term: Papilloma viral infection NOSSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056576Term: Cervical intraepithelial neoplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2011-002035-26-FRGlaxoSmithKline Biologicals1,079